Open Orphan’s first volunteer receives intranasal Covid-19 vaccine in clinical trial

Dublin-listed Open Orphan has reported that its first volunteer has been dosed in an intranasal Covid-19 vaccine clinical trial.

The volunteer was treated with the Codagenix needle free, intranasal Covid-19 vaccine called COVI-VAC.

COVI-VAC is a single-dose vaccine against SARS-CoV-2, the virus that causes Covid-19. It contains the entire virus in a weakened form.

The clinical trial is being conducted by Open Orphan subsidiary Hvivo at its London facility.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Open Orphan spin-out Poolbeg Pharma to list on London market

Dublin-listed pharmaceutical services company Open Orphan will seek admission of its spin-out company Poolbeg Pharma to trade on the London Stock Exchange’s AIM, using the funds raised to meet the costs of the clinical trials for its flu treatment. Poolbeg Pharma, which

Open Orphan Plc

Open Orphan updates on demerger

Further to Open Orphan plc (LON:ORPH) announcement on 14 June 2021 in relation to the distribution in specie, the boards of Open Orphan and Poolbeg Pharma are pleased to announce Poolbeg’s intention to seek admission of its shares to trading on

Open Orphan Plc

Open Orphan Distribution in Specie and Notice of Results

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that, further to previous announcements, it proposes to make a

Open Orphan Plc

End-to-end Drug Development & Clinical Research services

Venn Life Sciences is an Integrated Drug Development Partner offering aunique combination of drug development expertise and clinical trialdesign and management. This enables us to create, plan and execute drugand medical device development programs effectively and seamlessly forour

Open Orphan Plc

Planning a Clinical Trial? – Think Smart Design

By using smart designs, sponsors can save time and money while optimizing the knowledge accrued during the development of their products. “Traditional” study designs and statistical methodology do not allow changing the main features of a study protocol

Open Orphan Plc

Venn Life Sciences

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses